Biohope Announces Collaboration to Advance Immunobiogram for Renal Transplant
Madrid, Spain, November 3rd, 2025 – Biohope, a Spanish company specialized in personalized medicine solutions for transplant and autoimmune patients, has signed a know-how agreement with Mayo Clinic, a global leader in medical research and patient care, to advance the development and commercialization of the Immunobiogram, an in vitro diagnostic (IVD) device developed by Biohope and patented in the U.S. and other territories. The agreement grants Biohope access to Mayo Clinic’s specialized know-how, and seeks to enhance the clinical validation of the Immunobiogram in the US. This technology aims to optimize immunosuppression management by providing personalized diagnostic insights, potentially reducing rejection rates, infections, and improving graft survival and patient-reported outcomes (PRO). “We are thrilled to collaborate with Mayo Clinic, to utilize their expertise in transplant medicine,” said Isabel Portero, CEO of Biohope. “This agreement marks a significant step toward our goal of bringing Immunobiogram technology to market and offering transplant patients and clinicians a transformative tool for personalized immunosuppression management.” About Biohope Biohope is a biotechnology company dedicated to developing innovative diagnostic solutions for transplant patients. Its patented Immunobiogram technology provides personalized insights into immunosuppression sensitivity, aiming to enhance patient outcomes and quality of life. Note: Mayo Clinic has a financial interest in the [...]
Biohope Publishes New Pilot Study in Rheumatoid Arthritis, Opening the Path to a Novel Predictive Test
Biohope is proud to announce the publication of its latest scientific contribution in PLOS ONE: “Precision Medicine in Rheumatoid Arthritis: Evaluation of a New Approach to Predict Clinical Response to Methotrexate in Patients with Early Rheumatoid Arthritis”. This pilot clinical study explored whether simple in vitro blood tests could help predict which patients with early, methotrexate-naïve rheumatoid arthritis would respond to methotrexate, the gold-standard first-line therapy. The study followed 31 patients for six months and revealed that those who eventually achieved clinical remission showed distinct biological profiles before treatment. Specifically, the analized biomarkers demonstrated a high predictive capacity, suggesting that clinicians may be able to identify likely responders before initiating therapy. Although larger studies are required to confirm these findings, the general conclusion is clear: early prediction of methotrexate response through peripheral blood tests may soon become a reality. This opens the way for precision medicine approaches in rheumatoid arthritis, reducing delays in effective treatment and sparing patients from unnecessary exposure to ineffective therapies. At Biohope, we are transforming this knowledge into innovation. The encouraging results of this pilot study pave the way for the development of a new predictive diagnostic product that could guide therapeutic decisions in rheumatoid arthritis. We are pleased to [...]
Biohope presents the results of the BIOTRAIM study at the WTC’25 and they are selected among the most relevant abstracts in kidney transplantation
Biohope participated in the World Transplant Congress (WTC 2025) in San Francisco from 3 to 6 August 2025. We presented two oral communications on the results of the BIOTRAIM study. The WTC 2025 was the most important event of the year in the field of transplantation, as this edition integrated the ATC (American Transplant Association) congress, which was held separately in previous years. With the aim of addressing the issues that concern nephrologists around the world the most, Dr Ali reviewed the 1,550 abstracts submitted to the congress in the field of renal transplantation, making an initial selection of 50 and a final selection of 30. The abstract presented by Biohope, with the results of the BIOTRAIM study, was selected and its results were presented at the closing plenary session ('Reflection, Revelations and the Road Ahead'), in which the most relevant data from the congress are summarised. The WTC congress represents a strategic opportunity for Biohope to raise awareness of its technology and the results of its clinical research studies among the international transplant community. It is a space for interaction with thought leaders and companies from around the world, as well as a forum for scientific updates in this field. Biohope aims to [...]
Biohope is pleased to welcome Andrea Espigares Correa, MD, as our new Clinical Science Director
Andrea brings broad clinical and research experience, with a strong foundation in internal medicine and a deep commitment to advancing patient-centered innovation. Her work spans various healthcare systems and therapeutic areas, contributing to a holistic understanding of clinical development and patient care. She has played a key role in the design and execution of international clinical trials, including projects involving combination product medical devices such as autoinjectors and pre-filled syringes. Andrea also has experience in conducting competitive intelligence analyses to support strategic decision-making and ensure alignment with evolving scientific and regulatory landscapes. Andrea’s dedication to humanized medicine, digital transformation, and equitable access to healthcare aligns perfectly with Biohope’s mission. We are excited to welcome her to the team and look forward to the valuable contributions she will bring to our innovation efforts and patient-focused goals.
Biohope Welcomes Joshua Lee as Medical Director for US
Biohope is delighted to announce the appointment of Joshua Lee, MD, as the Medical Director for US. He has a diverse background in medical affairs and product launch in Cardiovascular, Nephrology, and Transplant therapeutic areas. With 14 years of experience, including AstraZeneca, Hansa Biopharma, and Immucor, he has worked in a variety of transplant roles in both pharmaceutical and biotech development bringing an essential component to our US development. Josh holds a Medical Doctorate from Xavier University School of Medicine and previously was involved in kidney and lung cancer research at the National Cancer Institute. He has been involved in developing and implementing numerous clinical trials, generating publications, and has vast experience working with regulatory. In his previous roles as medical director, he has published efforts in transplant equity and access, investigated gene expression's role in preventing transplant rejection, and engaged with numerous stakeholders and key opinion leaders in the transplant community. We welcome Josh to the Biohope Family! His passion for patients and advancing transplant will be a great asset to our goal of bringing IMBG to physicians and patients!
Biohope Receives an Honorary Plaque from the Spanish Association of Scientists in Recognition of Its Work in Developing Precision Medicine Diagnostic Tools
Biohope Receives an Honorary Plaque from the Spanish Association of Scientists in Recognition of Its Work in Developing Precision Medicine Diagnostic Tools Madrid, November 25th, 2024. The Spanish Association of Scientists held the XXVI Edition of the 2024 Honorary Plaques Awards on Thursday, November 21st, where Biohope was named the winner in the "Entities and Companies" category. Dr. Enrique de la Rosa, scientific researcher at the Margarita Salas Center for Biological Research (CIB-CSIC) and First Vice President of the Spanish Association of Scientists, presented the Honorary Plaque to Dr. Isabel Portero, CEO and founder of Biohope. The award recognizes the company’s mission to develop precision medicine diagnostic tools that enable a unique understanding of each patient and personalized therapy for their condition. Each year, the Spanish Association of Scientists awards Honorary Plaques to distinguished researchers in the “Outstanding Scientists” category. Additionally, companies that excel in scientific-technological research and innovation, as well as individuals, foundations, and organizations dedicated to science communication and dissemination in Spain, are also honored. In this XXVI Edition, other awardees in the “Scientists” category included Dr. Guillermo Monrós, Professor in the Department of Organic and Inorganic Chemistry at Universitat Jaume I de Castelló; Dr. Luis Blanco, Research Professor at the Severo Ochoa [...]
Spanish biotech Biohope develops a first in class device to personalize the first line of treatment for rheumatoid arthritis
The Community of Madrid grants the company, which received the Seal of Excellence of the European Innovation Council's Accelerator program, a grant of two million euros to carry out the project The economic burden of rheumatoid arthritis in Europe is estimated at 45billion euros Madrid, 6th November 2024. Rheumatoid arthritis is a chronic inflammatory disease that affects around 300,000 people in Spain.[1] The disease impacts their quality of life while also shortening their life expectancy. In terms of direct and indirect costs, the economic burden is estimated to be 45 billion[2] euros in Europe. While methotrexate (MTX) is a first-line treatment it is ineffective in half of the patients. The problem so far has been to identify those patients that would not benefit from the treatment. To address this issue the Spanish biotechnology company Biohope is developing the first pharmacological in vitro diagnostic (IVD) test to predict this clinical response. The team behind the launch of this precision medicine tool, MTX-CELL test, has just received a grant of two million euros from the community of Madrid to execute the project. This special grant is awarded to companies that, like Biohope, have obtained the Seal of Excellence within the framework of the European Innovation Council's Accelerator [...]
Biohope Secures Near-Maximum Funding in Madrid’s 2023 Call for Innovative SMEs
Madrid, September 2024 — Biohope, a pioneering biotech company, has been awarded €248,714.34 in funding under the 2023 call for support to innovative small and medium-sized enterprises (SMEs) by the Community of Madrid. This amount is just shy of the maximum possible grant of €250,000, highlighting the project's strong evaluation and strategic relevance. The funding falls under Line 3: Innovative SMEs with more than five years of activity, aimed at boosting mature companies with a proven track record in innovation. Biohope’s project, titled “Evaluation, for functional cell testing, of the stability and quality of peripheral blood mononuclear cells (PBMCs) over time,” will officially commence in September 2024. The initiative is expected to conclude by the end of the first quarter of 2026. This research aims to enhance the reliability and performance of PBMCs in functional assays, which are critical for immunological diagnostics and therapeutic monitoring. The project aligns with Biohope’s mission to advance personalized medicine through robust immunological tools. With this support, Biohope continues to strengthen its position as a leader in immunology-focused innovation, contributing to the development of cutting-edge solutions for transplant medicine and beyond.